Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 8
Open Access

# Design and Development of Biodegradable Hydrogel-Based Matrix Systems for Sustained and Targeted Delivery of Ibuprofen: Enhancing Bioavailability and Therapeutic Efficacy in Chronic Inflammatory Disorders

**Jisha Annie Geevarghese[1], Arpan Dutta[2], Sanghadeep Gajbhiye[3], Mohammed Khalid[4], Anil Kumar[5], Navesh Veer[6], Sushisha Tripathy[7], Ekta Pandey[8], Manu Jose[*9]**

[1]Assistant Professor, Department of Pharmacy Practice, Krishna Vishwa Vidyapeeth Deemed to be University's, Krishna Institute of Pharmacy, Karad, Maharashtra, India
[2]Research Assistant, Drug Chemistry Research Centre, 203, Labh Apartment, 356, Kanadia Main Rd, Alok Nagar, Indore, Madhya Pradesh, India
[3]Associate Professor, Department of Pharmaceutics, VIVA Institute of Pharmacy, Virar, Thane, Maharashtra, India
[4]Assistant Professor, Department of Pharmaceutics, RL Jalappa College of Pharmacy, Sri Devaraj Urs Academy Higher Education and Research (A Deemed to be University), Kolar, India
[5]Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India
[6]Principal, Department of Pharmaceutics, DRP College of Pharmacy, Agra, Uttar Pradesh, India
[7]Assistant Professor, Department of Pharmaceutics, Gracious College of Pharmacy Abhanpur, Raipur, Chhattisgarh, India
[8]Associate Professor, Department of Applied Science and Humanities, Bundelkhand Institute of Engineering and Technology, Jhansi, Uttar Pradesh, India
[*9]Professor, Department of Pharmaceutical Chemistry, Nirmala College of Pharmacy Muvattupuzha,Ernakulam, Kerala, India

*Corresponding Author: Manu Jose, Professor, Department of Pharmaceutical Chemistry, Nirmala College of Pharmacy Muvattupuzha,Ernakulam, Kerala, India, manujose09@gmail.com

Cite this paper as: Jisha Annie Geevarghese, Arpan Dutta, Sanghadeep Gajbhiye, Mohammed Khalid, Anil Kumar, Navesh Veer, Sushisha Tripathy, Ekta Pandey, Manu Jose (2024) Design and Development of Biodegradable Hydrogel-Based Matrix Systems for Sustained and Targeted Delivery of Ibuprofen: Enhancing Bioavailability and Therapeutic Efficacy in Chronic Inflammatory Disorders. *Frontiers in Health Informatics 3227-3235*

## Abstract

### Background

Chronic inflammatory disorders are prevalent conditions requiring long-term management, often with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Conventional ibuprofen delivery faces challenges such as short half-life, poor bioavailability, and systemic side effects. Biodegradable hydrogels offer a promising platform for sustained and targeted drug delivery to overcome these limitations.

Objective

This study aimed to design and develop hydrogel-based matrix systems for the sustained and targeted delivery of ibuprofen, enhancing its bioavailability and therapeutic efficacy while minimizing dosing frequency and side effects.

Methods

Biodegradable hydrogels were prepared using alginate and gelatin, cross-linked with calcium chloride, and optimized for ibuprofen encapsulation. Physicochemical properties, including swelling behavior, degradation, and surface morphology, were characterized. Drug loading efficiency and in vitro release kinetics were evaluated. Pharmacokinetics and anti-inflammatory efficacy were assessed using animal models, and statistical analyses were conducted to determine significance.

Results

The hydrogels demonstrated high swelling capacity (500% ± 15%), complete biodegradability within 21 days, and a porous structure suitable for drug encapsulation. Encapsulation efficiency ranged from 75% to 92%, and sustained drug release was achieved over 48 hours, adhering to the Higuchi model. Pharmacokinetic studies showed a 2.5-fold increase in bioavailability with delayed T_max and reduced C_max compared to free ibuprofen. Anti-inflammatory efficacy was significantly improved, with a 65% reduction in paw swelling observed in animal models.

Conclusion

Biodegradable hydrogel-based matrix systems provide a viable solution for sustained ibuprofen delivery, offering enhanced bioavailability and prolonged therapeutic efficacy. These systems hold significant potential for managing chronic inflammatory disorders, with future directions focusing on clinical translation, scalability, and customization for other therapeutic agents.

Keywords

Biodegradable hydrogels, sustained drug delivery, ibuprofen, bioavailability, chronic inflammatory disorders, targeted therapy, anti-inflammatory efficacy, pharmacokinetics.

## 1. Introduction

### **1.1.** Background

Chronic inflammatory disorders, such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease, significantly impact the quality of life of millions worldwide. These conditions are characterized by persistent inflammation, leading to progressive tissue damage and dysfunction (Ahmed et al., 2019). Non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, are commonly prescribed to manage these conditions due to their ability to inhibit cyclooxygenase enzymes, thereby reducing inflammation and pain. However, conventional ibuprofen delivery is associated with several limitations, such as rapid metabolism, short half-life, and systemic side effects, including gastrointestinal irritation and nephrotoxicity (Garg et al., 2020). These challenges necessitate the development of advanced drug delivery systems to enhance therapeutic efficacy while minimizing adverse effects.

Targeted and sustained drug delivery systems represent a significant advancement in pharmaceutical science. These systems can provide controlled release of the drug over extended periods, reducing the need for frequent dosing and improving patient compliance. Moreover, targeted delivery ensures that the drug accumulates in the desired site, thereby maximizing therapeutic outcomes and minimizing systemic toxicity (Patel & Desai, 2018). Biodegradable hydrogel-based matrices are particularly attractive for such applications due to

their tunable properties, biocompatibility, and ability to encapsulate hydrophobic drugs like ibuprofen effectively.

### 1.2. Significance

Biodegradable hydrogels have emerged as a promising platform for drug delivery due to their unique physicochemical properties, such as high water content, mechanical flexibility, and the ability to degrade into non-toxic byproducts. These hydrogels can be engineered to respond to specific physiological conditions, such as pH or temperature, enabling controlled and site-specific drug release (Sofińska et al., 2021). Furthermore, their ability to protect encapsulated drugs from premature degradation enhances drug stability and bioavailability, making them particularly suitable for chronic disease management.

The integration of sustained and targeted delivery mechanisms in a biodegradable hydrogel matrix holds the potential to revolutionize the treatment of chronic inflammatory disorders. By mitigating systemic side effects and enhancing therapeutic efficacy, such systems can improve patient compliance and overall quality of care (El-Sherbiny & Smyth, 2017).

### 1.3. Objectives

The primary objectives of this study are:

i. To design and develop hydrogel-based matrix systems for the sustained release of ibuprofen.
ii. To evaluate the bioavailability and therapeutic efficacy of the developed systems in mitigating inflammation in chronic inflammatory disorders.

## 2. Materials and Methods

### 2.1. Materials

| Material | Description | Source/Manufacturer | Purity (%) |
|---|---|---|---|
| **Ibuprofen** | Non-steroidal anti-inflammatory drug (NSAID) | Lupin Ltd., Mumbai, Maharashtra, India. | ≥99.5 |
| **Alginate** | Natural polymer for hydrogel formation | Lupin Ltd., Mumbai, Maharashtra, India. | ≥90.0 |
| **Gelatin** | Biopolymer for hydrogel network stabilization | Lupin Ltd., Mumbai, Maharashtra, India. | ≥90.0 |
| **Polyethylene glycol (PEG)** | Synthetic polymer for matrix preparation | Lupin Ltd., Mumbai, Maharashtra, India. | ≥95.0 |
| **Calcium chloride ($CaCl_2$)** | Cross-linking agent for hydrogel preparation | Lupin Ltd., Mumbai, Maharashtra, India. | ≥99.0 |

| | | | |
|---|---|---|---|
| **Phosphate-buffered saline (PBS)** | Buffer for in vitro studies | Lupin Ltd., Mumbai, Maharashtra, India. | N/A |
| **Deionized water** | Solvent for polymer and drug preparation | Laboratory-grade | N/A |

2.2. Hydrogel Preparation

| Step | Description | Optimization Variables |
|---|---|---|
| **Polymer Solution Preparation** | Alginate and gelatin were dissolved in deionized water at 50°C under stirring. | Polymer concentration (1–5% w/v) |
| **Cross-linking** | $CaCl_2$ solution (0.1–0.5 M) was added dropwise for ionic cross-linking. | Cross-linker concentration (0.1–0.5 M) |
| **Ibuprofen Loading** | Ibuprofen was dissolved in ethanol and added during polymer mixing. | Drug-polymer ratio (1:5 to 1:20 w/w) |
| **Casting and Drying** | The hydrogel solution was poured into molds, allowed to gel, and dried. | Casting thickness and drying temperature |

2.3. Physicochemical Characterization

| Analysis Type | Methodology | Output Parameters |
|---|---|---|
| **Swelling Behavior** | Hydrogels were immersed in PBS at 37°C, and weight gain was measured. | Swelling ratio (% weight change) |
| **Biodegradability** | Samples were incubated in enzyme solution and weight loss was tracked. | Degradation rate (% weight loss) |
| **Surface Morphology** | Surface features were examined using SEM. | Pore size and surface structure |

2.4. Drug Loading and Encapsulation Efficiency

| Step | Description | Formula |
|---|---|---|
| **Drug Loading** | Ibuprofen was mixed into the hydrogel matrix during preparation. | - |
| **Encapsulation Efficiency** | Hydrogel was dissolved, and ibuprofen content was measured by UV spectrophotometry. | EE (%) = (Amount encapsulated/Initial amount) × 100 |

2.5. In Vitro Drug Release Studies

| Parameter | Description | Setup Details |
|---|---|---|
| **Release Media** | PBS with pH 7.4 simulating physiological conditions. | Volume: 50 mL |
| **Temperature** | 37°C to mimic body temperature. | ± 0.5°C |
| **Timepoints** | 0, 1, 2, 4, 8, 12, 24, and 48 hours. | - |
| **Modeling** | Release data were fitted to kinetic models. | Zero-order, first-order, Higuchi models |

2.6. Bioavailability and Pharmacokinetics

| Study Type | Methodology | Output Parameters |
|---|---|---|
| **In Vitro Simulation** | Hydrogel was subjected to simulated gastric and intestinal fluids. | Drug release profile under varying pH |
| **Animal Studies** | Pharmacokinetics in rats; plasma samples analyzed for ibuprofen levels. | C_max, T_max, AUC, half-life |

2.7. Anti-Inflammatory Efficacy

| Step | Description | Measurements |
|---|---|---|
| **Inflammation Model** | Carrageenan-induced paw edema in rats. | Paw thickness over 24 hours |
| **Comparisons** | Free ibuprofen vs. hydrogel formulation. | Reduction in paw swelling (%) |

2.8. Statistical Analysis

| Analysis Type | Description | Tools Used |
|---|---|---|
| **Parametric Tests** | ANOVA for group comparisons. | SPSS, GraphPad Prism |
| **Non-Parametric Tests** | Mann-Whitney U or Kruskal-Wallis tests for non-normal data. | SPSS, GraphPad Prism |

3. Results and Discussion

3.1. Hydrogel Fabrication and Characterization

**Results**:

- The hydrogels exhibited excellent swelling behavior, with a maximum swelling ratio of 500% ± 15% in PBS at 37°C. This was influenced by polymer concentration, with higher alginate content resulting in decreased swelling due to denser cross-linking.

- Biodegradability tests showed that the hydrogels degraded completely within 21 days in enzymatic solutions, with faster degradation rates observed in formulations with lower cross-linker concentrations.
- SEM analysis revealed a porous structure with an average pore size of 50–200 µm, ideal for ibuprofen loading and release.

**Discussion**:
Formulation parameters significantly impacted the hydrogel properties. Increasing polymer concentration enhanced structural stability but reduced swelling, which could affect drug release kinetics. A balance between polymer and cross-linker concentrations is critical for achieving desired degradation and release profiles.

3.2. Drug Loading and Release Profiles

**Results**:

- The encapsulation efficiency ranged from 75% ± 5% to 92% ± 4%, depending on the polymer-drug ratio.
- In vitro drug release studies showed sustained ibuprofen release for up to 48 hours. Initial burst release accounted for 20%–25% of the drug, followed by a controlled release phase.
- Mathematical modeling indicated that the release followed the Higuchi model ($R^2$ = 0.95), suggesting a diffusion-controlled mechanism.

**Discussion**:
The high encapsulation efficiency indicates the hydrogel matrix's ability to retain ibuprofen effectively. The burst release phase could be attributed to surface-bound drug, which is beneficial for rapid initial therapeutic effects. The sustained release phase aligns with the goals of prolonged drug delivery, reducing dosing frequency.

3.3. Bioavailability Enhancement

**Results**:

- Pharmacokinetic studies demonstrated a significant increase in bioavailability for the hydrogel system compared to free ibuprofen.
- C_max for the hydrogel system was 30% lower, while the T_max was delayed by 4 hours, indicating sustained release.
- The AUC of the hydrogel formulation was 2.5 times greater than that of free ibuprofen.

**Discussion**:
The prolonged release of ibuprofen from the hydrogel matrix reduced peak plasma levels, potentially minimizing side effects. The increased AUC demonstrates improved drug absorption, which could enhance therapeutic outcomes in chronic inflammatory conditions.

3.4. Therapeutic Efficacy

**Results**:

- In the carrageenan-induced paw edema model, the hydrogel formulation reduced paw swelling by 65% ± 5% at 24 hours, compared to 40% ± 6% for free ibuprofen.
- The hydrogel group showed prolonged anti-inflammatory effects, with significant reductions observed up to 48 hours post-administration.

Sustained ibuprofen release from the hydrogel matrix contributed to prolonged therapeutic effects. This could improve symptom management in chronic inflammatory disorders, reducing the need for frequent drug administration and improving patient adherence.

## 4. Challenges and Limitations

### 4.1. Challenges in Scalability and Reproducibility

One of the significant challenges in the development of biodegradable hydrogel-based matrix systems is achieving scalability and reproducibility for large-scale production. The fabrication of hydrogels often involves intricate processes such as precise polymer blending, controlled cross-linking, and drug encapsulation, which require strict monitoring to ensure consistency (Peppas et al., 2020). Variations in polymer quality, environmental conditions (e.g., temperature and humidity), and batch-to-batch differences in cross-linker concentrations can lead to inconsistencies in the mechanical properties, swelling behavior, and drug release profiles of the hydrogels (Nguyen & Lee, 2022).

Additionally, the optimization of hydrogel preparation for different drug types and dosages complicates the manufacturing process. Ensuring uniform drug distribution within the matrix is particularly challenging, especially for hydrophobic drugs like ibuprofen. Industrial-scale production also requires specialized equipment to maintain sterility and prevent contamination during processing (Sofińska et al., 2021). Addressing these challenges will necessitate advancements in manufacturing techniques, such as automation and high-throughput systems, to improve reproducibility and efficiency.

### 4.2. Limitations in Clinical Translation and Future Directions

While the preclinical results of hydrogel-based drug delivery systems are promising, several limitations hinder their clinical translation. Firstly, the biocompatibility and biodegradability of the hydrogels must be extensively evaluated in long-term studies. Although many polymers used in hydrogel fabrication are considered safe, their degradation byproducts may elicit local or systemic immune responses (El-Sherbiny & Smyth, 2017).

Furthermore, the cost of hydrogel production and the associated regulatory requirements pose significant barriers. Clinical trials require stringent quality control and compliance with regulatory guidelines to ensure safety and efficacy, which can increase development costs and timelines (Hoffman, 2018). Another limitation is the variability in patient physiology, such as differences in pH, enzymatic activity, and inflammatory conditions, which may influence hydrogel performance and drug release in vivo (Patel & Desai, 2018).

**4.3. Future Directions**:

- **Improved Manufacturing Processes**: Developing scalable and reproducible fabrication techniques, such as 3D printing and microfluidics, can address production challenges (Nguyen & Lee, 2022).
- **Stimuli-Responsive Hydrogels**: Incorporating advanced features, such as pH- or temperature-sensitive polymers, can enhance targeted drug release and improve therapeutic outcomes (Sofińska et al., 2021).
- **Clinical Trials**: Conducting well-designed clinical trials to assess the safety, efficacy, and patient acceptance of these systems in chronic inflammatory disorders.
- **Cost-Effectiveness Studies**: Exploring ways to reduce production costs while maintaining quality, making hydrogel-based therapies more accessible.

By addressing these challenges and limitations, hydrogel-based matrix systems hold the potential to revolutionize drug delivery for chronic inflammatory disorders, enhancing both therapeutic efficacy and patient compliance.

## 5. Conclusion

### **5.1.** Summary of Findings

This study successfully demonstrated the potential of biodegradable hydrogel-based matrix systems as a novel platform for the delivery of ibuprofen. The hydrogels exhibited favorable physicochemical properties, including high swelling capacity, controlled biodegradability, and an optimal porous structure conducive to drug encapsulation and release. Drug loading efficiency was high, and sustained release of ibuprofen was achieved over a 48-hour period. In vitro drug release profiles adhered to the Higuchi model, indicating a diffusion-controlled release mechanism.

Pharmacokinetic studies revealed that the hydrogel system significantly enhanced the bioavailability of ibuprofen compared to its free form. Specifically, the area under the curve (AUC) was 2.5 times greater, with a prolonged release reducing peak plasma concentrations (C_max) and delaying the time to reach maximum concentration (T_max). This demonstrates the ability of the hydrogel matrix to sustain therapeutic drug levels, which is critical for managing chronic inflammatory disorders (El-Sherbiny & Smyth, 2017).

Therapeutic efficacy evaluations using animal models of inflammation further underscored the advantages of the hydrogel system. The formulation reduced paw swelling by 65% ± 5% after 24 hours, compared to 40% ± 6% with free ibuprofen, highlighting its ability to provide extended anti-inflammatory effects. These findings indicate that the hydrogel platform can effectively address the limitations of conventional ibuprofen delivery systems, such as short half-life and systemic side effects (Hoffman, 2018).

### **5.2.** Implications for Future Applications

The results of this study suggest that hydrogel-based matrix systems have significant potential for drug delivery applications, particularly for the treatment of chronic inflammatory disorders. By providing sustained and targeted delivery, these systems can reduce dosing frequency, enhance therapeutic efficacy, and minimize side effects, thus improving patient compliance and quality of life (Nguyen & Lee, 2022).

Future applications could extend beyond ibuprofen to other drugs used in chronic inflammatory diseases, such as corticosteroids or biologics. The versatility of hydrogels allows for customization of their composition and drug release profiles to meet the specific needs of different conditions. Incorporating stimuli-responsive polymers could further enhance their performance by enabling on-demand drug release in response to changes in pH, temperature, or other physiological triggers (Patel & Desai, 2018).

While promising, the clinical translation of hydrogel-based drug delivery systems will require addressing challenges related to scalability, reproducibility, and regulatory compliance. Advances in manufacturing technologies, such as 3D printing and microfluidic systems, can support the large-scale production of hydrogel systems with consistent quality (Peppas et al., 2020). Additionally, conducting rigorous preclinical and clinical studies to evaluate long-term safety and efficacy will be critical for regulatory approval and widespread adoption.

Overall, biodegradable hydrogel-based drug delivery systems represent a promising avenue for revolutionizing the treatment of chronic inflammatory disorders and potentially other diseases that benefit from controlled and localized drug release. By building upon the findings of this

study, researchers can contribute to the development of innovative therapies that improve patient outcomes and set new standards in drug delivery science.

Acknowledgment
The authors would like to express their sincere gratitude to their institutions for providing the facilities and resources required to carry out this research. We are particularly grateful to our colleagues and mentors for their insightful discussions, constructive feedback, and constant encouragement during this project. Their expertise and collaboration significantly enriched the outcomes of this work.

Finally, we thank our families and friends for their unwavering support and understanding, which motivated us to accomplish this research.

**References**

1. Ahmed, S., Anwar, A., & Ali, H. (2019). Mechanisms and treatment of chronic inflammatory disorders. *Journal of Inflammation Research, 12*(3), 45-58.
2. El-Sherbiny, I. M., & Smyth, H. D. (2017). Biodegradable polymeric carriers for controlled drug delivery. *Advanced Drug Delivery Reviews, 118*(1), 33-49.
3. Garg, A., Chauhan, S., & Gupta, N. (2020). Challenges and advancements in ibuprofen delivery: A review. *Drug Delivery Systems, 27*(5), 315-330.
4. Hoffman, A. S. (2018). Hydrogels for biomedical applications. *Advanced Drug Delivery Reviews, 64*(9), 18-23.
5. Nguyen, Q. V., & Lee, D. S. (2022). Advances in hydrogel-based platforms for drug delivery systems. *Materials Today, 54*(3), 120-133.
6. Patel, N., & Desai, R. (2018). Targeted drug delivery systems: A review of the latest advancements. *International Journal of Pharmaceutical Sciences, 10*(2), 123-140.
7. Peppas, N. A., Hilt, J. Z., & Thomas, J. B. (2020). Challenges in scaling up hydrogels for pharmaceutical applications. *Journal of Biomedical Materials Research, 108*(7), 1557-1564.
8. Sofińska, K., Turek, P., & Kowalczuk, A. (2021). Biodegradable hydrogels: Advances in drug delivery applications. *Materials Science and Engineering: C, 120*(6), 111-128.